Direct effects of PPARγ activation on adipose tissue lipid metabolism and endocrine function may be linked with secondary benefits in liver and muscle lipid metabolism and insulin signalling and suggest that PPARγ is an important target for pharmacotherapy to tackle the metabolic syndrome and obesity-related insulin resistance. This evidence concerns the gene INS and metabolic syndrome.